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Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality.
Evidence of interstitial lung disease (ILD) is seen in 80% of patients with SSc. Currently there is no
approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is
included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is
becoming the most commonly used medication in clinical practice in North America and the UK, but
its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including
fibrotic and inflammatory pathways, lymphocytes, cellcell and cellextracellular membrane interactions,
hold promise for better treatment outcomes, including improved lung function, patient-related outcomes
and quality of life. Here we review ongoing trials of established and novel agents that are currently
recruiting patients with SSc-ILD.
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Rheumatology key messages
. There are no approved disease-modifying treatments for SSc-associated interstitial lung disease and few effect-
ive therapies.
. Newer agents show better outcomes in SSc-associated interstitial lung disease, including improved lung function.
Introduction
SSc is a rare CTD that affects multiple organ systems,
resulting in substantial morbidity and mortality [1]. The
pathogenesis of SSc is not fully understood, but may in-
volve interactions between genetic susceptibility loci
[including MHC class II genes and genes associated
with extracellular matrix (ECM) metabolism and control
of immune function] and environmental factors [2].
The presentation and clinical course of SSc are hetero-
geneous, and the classification developed by the ACR
and EULAR is based on the extent of skin fibrosis and
pattern of internal organ involvement [3]. Patients with
SSc can be subdivided into two main categories, limited
(60% of patients) and diffuse cutaneous (30%), the re-
maining 10% of patients having rarer subtypes [1, 2, 4].
In dcSSc, fibrosis of the skin, lungs and other internal
organs progresses rapidly, with early development of vis-
ceral organ complications. In contrast, lcSSc primarily
features vascular manifestations with mild skin fibrosis,
although organ fibrosis can be significant.
Key features of SSc are vasculopathy, dysregulation of
innate and adaptive immunity, and fibrosis of skin and
visceral organs [2]. Fibrosis results from a complex inter-
play of the immune system with activated fibroblasts,
leading to ECM accumulation in skin and organs. While
skin fibrosis is the most common feature, fibrosis of in-
ternal organs leads to organ damage and poor clinical
outcome. Data from the European Scleroderma Trials
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and Research (EUSTAR) group registry confirm that dis-
ease-related causes, particularly pulmonary fibrosis, pul-
monary hypertension (PH) and heart disease, account for
the majority of deaths in SSc [5]. However, survival has
improved in recent decades, with a retrospective study in
the UK showing that 5-year survival improved from 69% in
patients with disease onset in 199093 to 84% in those
with onset in 200003 (P= 0.018), as a result of more com-
plete ascertainment of lung complications [6]. In a
Canadian study published in 2010, 5- and 10-year survival
was 95 and 92%, respectively, for lcSSc but only 81 and
65% for dcSSc [7].
Key organ systems are affected in SSc, including the
musculoskeletal, skin, gastrointestinal and pulmonary
systems [1, 3]. Musculoskeletal manifestations affect
joints (arthralgia, synovitis, contractures), tendons
(tendon friction rubs, tenosynovitis) and muscles (myalgia,
muscle weakness, myositis), while skin manifestations in-
clude skin fibrosis and thickening, as well as RP, digital
ulcers and calcinosis [1]. Gastrointestinal manifestations
include dysphagia, heartburn, distension, bloating, ab-
dominal pain, nausea, vomiting, diarrhoea, constipation
and faecal incontinence [8].
The two most important forms of pulmonary involve-
ment in SSc are interstitial lung disease (ILD) and PH.
Around 80% of patients with SSc show lung fibrosis,
with 2530% developing progressive ILD [1]. Typical
symptoms include cough, limited exercise tolerance,
chest pain and dyspnoea [9]. Using high-resolution CT
(HRCT), the most common findings of ILD include reticu-
lation, ground-glass opacities and honeycombing [10].
Progression can lead to more extensive lung changes,
with worsening of fibrosis.
Dyspnoea alone is insufficient to diagnose ILD, as there
are other potential causes in patients with SSc [11].
Diagnosis involves pulmonary function tests (PFTs), dif-
fusing capacity of the lung for carbon monoxide (DLCO)
and imaging [12]. In SSc-ILD, initial PFTs may reveal a
restrictive pattern, with reduced forced vital capacity
(FVC) and a normal or slightly increased forced expiratory
volume in 1 sec (FEV1):FVC ratio. Importantly, PFTs may
be normal in very early ILD and cannot be used to rule it
out. DLCO is particularly important as it provides an as-
sessment of the interstitial space between alveolar and
endothelial surfaces and the integrity of the lung vascular
bed. It is probably the most sensitive test of worsening
pulmonary involvement in SSc, although it lacks specifi-
city in differentiating ILD from pulmonary vascular dis-
ease. Reduced DLCO out of proportion to reduced FVC
(e.g. FVC:DLCO ratio >1.6) suggests significant pulmon-
ary vascular disease [13]. HRCT, unlike conventional radi-
ography, has high sensitivity and specificity for detecting
parenchymal involvement in patients with SSc, and is
therefore mandatory for diagnosing SSc-ILD. HRCT
should always include prone images to confirm that mild
bibasilar changes are not due to atelectasis. Open lung
biopsy is generally not performed.
Patients with SSc should be monitored early in their
condition, with serial spirometry and DLCO measurements
throughout their disease. If ILD is confirmed, the change
in lung function during treatment should be monitored
[1, 11, 12]. Accounting for measurement error in FVC
and DLCO, the OMERACT group defines progressive
ILD as either a 510% relative decline in FVC or a decline
in FVC of 59% and in DLCO of515% [14]. The changes
should be confirmed by repeat testing to show that they
are sustained. This definition has recently been validated
as a predictor of mortality in SSc-ILD [15].
Given the wide range of potential symptoms in patients
with SSc, the management of SSc-ILD is of great rele-
vance to clinicians across several therapy areas.
Unmet medical need in SSc-ILD
SSc remains difficult to treat, with limited options [16].
Few randomized studies have been conducted, effect
sizes for existing drugs are small and there is no approved
disease-modifying therapy. Patients may therefore re-
ceive several different immunosuppressive therapies for
complications involving skin and internal organs. Their
impact is modest, especially in the skin, and they are
associated with adverse events [1719] that have import-
ant lifestyle consequences. Local reimbursement and
payment for multiple treatments are also factors to
consider.
Treatments evaluated for SSc-ILD
CYC
CYC is a nitrogen mustard alkylating agent and potent
immunosuppressive used to reduce inflammation and
prevent fibrosis (Fig. 1) [20]. Efficacy in SSc-ILD was ini-
tially demonstrated in retrospective studies, suggesting
that treatment could slow the decrease in FVC over
time, potentially improving FVC in some patients [21].
However, results from observational studies are mixed,
as not all studies show improved lung function [20, 22].
CYC has substantial toxicity, notably haemorrhagic cyst-
itis and immunosuppression, as well an increased risk of
malignancy, infection, nausea, vomiting and hair loss and
less frequent cardiac, renal, genitourinary, pulmonary and
hepatic toxicity [17].
CYC in patients with SSc, restrictive lung physiology,
dyspnoea and evidence of inflammatory ILD was evalu-
ated in the Scleroderma Lung Study (SLS) I [23] (Table 1).
In this randomized, double-blind trial, 158 patients
received daily CYC (42 mg/kg) or placebo for 1 year and
were followed for an additional year. The primary endpoint
was FVC (percentage of predicted value, adjusted for
baseline FVC) at 12 months, with a mean absolute treat-
ment difference of 2.53% (95% CI 0.28, 4.79; P< 0.03)
favouring CYC [23]. There were also benefits in total
lung capacity, dyspnoea and quality of life (QoL).
Benefits of CYC on pulmonary function continued to in-
crease for 18 months (i.e. 6 months after treatment was
withdrawn), with a positive effect on dyspnoea for
2 years [24]. However, adverse events (AEs), including
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haematuria, leukopenia and neutropenia, were more fre-
quent with CYC vs placebo [23].
In a second placebo-controlled trial [the Fibrosing
Alveolitis in Scleroderma Trial (FAST)], 45 patients were
randomized to placebo or active treatment (prednisolone
20 mg on alternate days and six infusions at 4-week inter-
vals of CYC 600 mg/m2 followed by AZA 2.5 mg/kg/day as
maintenance therapy) [25]. The primary endpoints were
the change in the percentage predicted FVC and haemo-
globin-corrected DLCO, but after 12 months there were no
significant differences in lung parameters between the two
arms. There was, however, a trend to significance in treat-
ment difference for FVC change (4.2% in favour of active
treatment; P= 0.08) and no increase in serious AEs with
active treatment.
Based on these two trials, EULAR guidelines state that
CYC may be considered for the treatment of SSc-ILD [26].
MMF
MMF is a prodrug of MPA that inhibits a metabolic path-
way essential for lymphocyte function (Fig. 1) [18].
Extensive prospective and retrospective studies in SSc-
ILD suggest that MMF may be effective in improving or
stabilizing ILD [18]. In the recent SLS II study, 142 patients
with SSc-ILD were randomized to oral MMF (titrated to a
target dose of 1500 mg twice daily) for 24 months or oral
CYC (titrated to a target dose of 2.0 mg/kg/day) for
12 months followed by placebo for 12 months (Table 1)
[27]. The primary endpoint was the percentage predicted
FVC at 24 months, and improvement was positive in both
treatment arms (MMF 2.2%, CYC 2.9%). While the be-
tween-treatment difference was not statistically signifi-
cant, the difference from baseline was statistically
significant for both treatments. Leucopenia and thrombo-
cytopenia were more frequent with CYC (41 and 6%, re-
spectively) than MMF (6 and 0%) and fewer MMF-treated
patients withdrew from treatment or met criteria for treat-
ment failure. Time to stopping treatment due largely to
AEs was significantly shorter with CYC (P= 0.019) (27).
Of course, these data do not allow us to draw compari-
sons between MMF and the short courses of i.v. CYC that
have previously been tested in this setting. In a large retro-
spective analysis in the UK, 109 MMF-treated patients
with dcSSc (61 with lung involvement) were compared
with 63 patients (40 with lung involvement) receiving
other immunosuppressive agents [6]. In the 5 years
after starting treatment there was a significantly lower
FIG. 1 Modes of action of existing and future candidate agents for the treatment of SSc-ILD
SSc-ILD has many potential targets for therapeutic agents [18, 20, 22, 50, 56, 64, 67, 70, 7375, 7779].
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frequency of clinically significant pulmonary fibrosis in the
MMF arm (P= 0.037) and significantly better 5-year sur-
vival from disease onset (P= 0.027) and start of treatment
(P= 0.012). There were no significant differences in mod-
ified Rodnan skin score (mRSS) and FVC change.
While generally well tolerated, MMF is associated with
gastrointestinal disturbances, myelosuppression and
increased risk of infection [18, 22]. An enteric formulation,
mycophenolate sodium, has been developed to reduce
the incidence of gastrointestinal side effects [28].
MMF is often the initial treatment of choice for patients
with SSc-ILD [22]. It is not, however, included in the 2013
EULAR guidelines [26], which were developed before SLS
II was published.
AZA
AZA is a non-selective immunosuppressant acting primar-
ily in lymphocytes to block purine synthesis and DNA rep-
lication [29]. It has been evaluated in an open-label study
in 60 patients randomized to CYC (2 mg/kg/day for
12 months followed by 1 mg/kg/day maintenance) or
AZA (2.5 mg/kg/day for 12 months followed by 2 mg/kg/
day maintenance) [30]. AZA was associated with signifi-
cant worsening of FVC and DLCO and is no longer con-
sidered a first-line treatment option for SSc-ILD. Several
observational studies have shown, however, that AZA
maintenance therapy after CYC induction can stabilize
lung function [12].
Corticosteroids
Corticosteroid monotherapy is ineffective, but corticoster-
oids are often combined with immunosuppressants be-
cause of their anti-inflammatory properties [12].
Furthermore, chronic use of moderate to high doses
(>15 mg/day) has been associated with a higher risk of
scleroderma renal crisis, regardless of other immunosup-
pressive therapy [31, 32]. As SSc-ILD generally involves
fibrotic non-specific interstitial pneumonia or usual inter-
stitial pneumonia (>95% of cases), the use of moderate to
high doses of steroids is questionable. Consequently,
clinical trials have used doses of prednisone of up to
10 mg/day, while physicians in the USA avoid prednisone
for management of ILD. In Europe, oral prednisolone
doses up to 10 mg are often given, although efficacy is
uncertain. This practice is supported by inclusion of pred-
nisolone in the FAST, as described above [25].
Bosentan
Endothelin 1 (ET-1) is implicated in the pathophysiology of
lung fibrosis and elevated levels have been detected in
plasma and bronchoalveolar lavage fluid from patients
with SSc-ILD [33]. There is therefore a rationale for eval-
uating drugs targeting ET-1 or its receptors.
Bosetan Use in Interstitial Lung Disease 2 (BUILD-2)
was a randomized, double-blind, placebo-controlled trial
in 163 patients with SSc-ILD, predicted DLCO <80% and
a 6-min walk distance of either 150500 m or >500 m with
a decrease in oxygen saturation [34]. Patients were
randomized to the ET-1 receptor antagonist bosentan
(62.5 mg twice a day, increasing to 125 mg twice a day
after 4 weeks) or placebo. Despite the clear rationale and
large population, there was no significant difference in the
6-min walk distance change at week 12 (primary endpoint)
between the bosentan (12 ± 100 m) and placebo
(+9 ± 84 m) arms. Furthermore, bosentan had no effect
on time to death or worsening PFTs [hazard ratio (HR)
1.10 (95% CI 0.56, 2.14)] or clinically significant worsening
at month 12 [relative risk 0.88 (95% CI 0.50, 1.56)].
Pomalidomide
Pomalidomide is an immunomodulator related to thalido-
mide with a range of effects, including anti-inflammatory
properties resulting from inhibition of cyclooxygenase-2
production and prostaglandin generation in lipopolysac-
charide-stimulated monocytes [35]. It also has direct and
indirect cytotoxic activity and is licensed for the treatment
of relapsed and refractory multiple myeloma [36].
Based on the anti-fibrotic activity in pre-clinical models,
23 patients with SSc-ILD were randomized to pomalido-
mide or placebo in a phase 2 study (Table 1) [37]. At week
52, changes in FVC%, mRSS and University of California,
Los Angeles Scleroderma Clinical Trial Consortium
Gastrointestinal Tract 2.0 instrument total score all fa-
voured placebo, so the study was terminated early for
lack of efficacy.
Rituximab
Rituximab is a CD20-targeted mAb causing rapid B cell
depletion and immunosuppression [38]. It is licensed for
treatment of non-Hodgkin lymphoma and chronic lympho-
cytic leukaemia, RA and granulomatosis with polyangiitis.
In a 1-year, proof-of-principle study, eight patients
with SSc-ILD received standard therapy plus 4 weekly
infusions of rituximab 375 mg/m2 at baseline and at
24 weeks, while six additional patients received standard
therapy only [39]. After 1 year there were significant in-
creases in FVC (P= 0.002) and DLCO (P= 0.023) in the
rituximab-treated patients compared with declines with
standard therapy. The mRSS also improved significantly
from baseline in the rituximab arm (P< 0.001).
Autologous haematopoietic stem cell transplantation
Autologous haematopoietic stem cell transplantation
(HSCT) as a means of ‘resetting’ the immune system
has shown promise in phase I and II studies in SSc-ILD
[22]. In the Scleroderma: Cyclophosphamide or
Transplantation study, 75 patients with dcSSc and a
high risk of lung and/or renal involvement were
randomized to receive monthly CYC (750 mg/m2) or mye-
loablation (800 cGy total body irradiation with lung and
kidney shielding, 120 mg/kg CYC and 90 mg/kg antithy-
mocyte globulin) followed by CD34+-selected autologous
HSCT (Table 1) [40]. The primary endpoint was a global
rank composite score at 54 months that ordered patients
based on a hierarchy of death, event-free survival, FVC,
scleroderma HAQ and mRSS. At 48 months (P= 0.008)
and 54 months (P= 0.013), global rank composite score
comparisons favoured HSCT. In addition, event-free
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survival at 54 months was 50 and 79% in the CYC and
HSCT arms, respectively (P= 0.021), and more patients
who received HSCT survived to 54 months (91%) com-
pared with CYC (77%). Serious AEs were similar in both
study arms, although grade 3+ AEs, including cytopenia
and herpes zoster, were more common with HSCT [40].
In the Autologous Stem Cell Transplantation
International Scleroderma study, 156 patients with early
dcSSc were randomized to HSCT or i.v. pulse CYC
(Table 1) [41]. The primary endpoint was event-free sur-
vival (time from randomization until death or persistent
major organ failure). Despite an increase in treatment-
related mortality in the first year in the HSCT arm (eight
deaths vs none with CYC), there were significantly fewer
cumulative events in the HSCT arm after 4 years [19 vs
26%; time-varying HR 0.34 (95% CI 0.16, 0.74)]. Based
on these promising results, HSCT is recommended for the
treatment of carefully selected patients with rapidly pro-
gressive SSc at risk of organ failure [26]. In particular,
HSCT with intensive immunosuppression has a substan-
tial benefit as rescue therapy in some patients with SSc,
especially those with lung fibrosis and poor prognosis [1,
42].
Non-pharmacological and symptomatic treatment
options
The cardinal respiratory symptom of SSc-ILD is dys-
pnoea. Measures that may be useful for treating disabling
dyspnoea not responding adequately to pharmacotherapy
for SSc-ILD include supplemental oxygen therapy for dys-
pnoea associated with significant oxygen desaturation
<88% either at rest or during exertion, pulmonary rehabili-
tation and, for intractable dyspnoea at rest, opiates. The
data available from randomized clinical trials concerning
the efficacy of supplemental oxygen therapy (compared
with air) were derived from patients mainly with idiopathic
pulmonary fibrosis, but also included patients with ILD
due to other causes, including SSc. The results are
mixed, with some studies showing a significantly greater
effect than placebo in improving exercise performance
(that is mainly limited by dyspnoea) and others not,
while one study showed a significant benefit for resting
dyspnoea [43]. Data regarding the benefits of pulmonary
rehabilitation are derived largely from chronic obstructive
pulmonary disease, but some studies have examined its
role in ILD. The results of these studies have largely shown
significant improvements in 6-min walk distance and
health-related QoL, with variable improvement in dys-
pnoea at rest and during exercise [44, 45]. Despite a
lack of published data in SSc-ILD, patients are routinely
referred for pulmonary rehabilitation to improve functional
exercise capacity and dyspnoea. Multiple randomized
controlled trials and systematic reviews have shown sig-
nificant reductions in intractable dyspnoea with oral or
parenteral opioids in patients with advanced disease,
including ILD [46]. Anxiolytics might be of added benefit
to minimize dyspnoea associated with anxiety.
Lung transplantation is usually reserved for patients
who are non-responsive to immunosuppressive therapy
for their ILD (with or without associated PH). In SSc-ILD,
consideration for lung transplantation is limited by the high
prevalence of comorbid oesophageal dysfunction, which
likely increases the risk of allograft dysfunction [47].
However, recent data suggest that survival outcomes
may be comparable to those in non-SSc diffuse fibrotic
lung disease due to better management of oesophageal
dysmotility. The 1-, 3- and 5-year post-lung transplant
survival rates for SSc-ILD in a recent retrospective
review from a large, single-centre database were 94, 77
and 70%, respectively, similar to rates in other groups
[47].
Gastro-oesophageal reflux can be associated with
silent aspiration that may result in worsening of ILD [48].
Patients with ILD should be advised to follow non-
pharmacological and pharmacological management stra-
tegies for gastro-oesophageal reflux, if appropriate.
Ongoing clinical trials in SSc-ILD
Several drugs are under investigation for SSc-ILD, includ-
ing existing and novel agents (Table 2). Examples of pre-
viously investigated agents are MMF and rituximab. MMF
is being investigated in the phase 3 MYILD study
(ClinicalTrials.gov: NCT02896205) in patients with SSc
and early, mild ILD (defined as FVC 570% of predicted).
The primary endpoint is FVC, and secondary endpoints
include FVC according to antibody (anti-centromere and
anti-topoisomerase1) profile, QoL (36-item Short Form),
Mahler Transition Dyspnoea Index and adverse
events. Rituximab is being investigated in the double-
blind phase 3 RECITAL study (ClinicalTrials.gov:
NCT01862926), in which 116 patients will be randomized
to rituximab (two 1 g i.v. infusions at an interval of 2 weeks)
or cyclophosphamide (600 mg/m2/month for up to
6 months) [49]. The study will enrol patients with connect-
ive tissue disease (SSc, idiopathic interstitial myopathy or
MCTD) and ILD and is expected to be completed in
November 2020.
Novel agents for treatment of SSc-ILD
Abituzumab
Integrins are heterodimeric transmembrane glycoproteins
consisting of one a and one b subunit. Integrins mediate
cellcell and cellECM interactions, including cell cycle
progression, cellular invasion and migration, signalling
and regulation of gene transcription [5054]. One import-
ant subfamily contains the av integrins, which are involved
in the regulation of cellECM adhesion, cellular prolifer-
ation and migration and activation of TGF-b [54, 55].
These properties of av integrins are the basis for their in-
volvement in several forms of cancer and led to the de-
velopment of specific inhibitors. TGF-b plays a pivotal role
in the regulation of lung fibrosis, and inhibition of TGF-b
can protect against lung fibrosis in animal models of lung
disease [56]. Notably, integrins bv3, bv5 and bv6 are upre-
gulated in the epithelium of some patients with SSc-ILD
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[5759]. Integrin av is involved in activating TGF-b, a key
mediator of fibrosis.
Abituzumab (EMD 525797; DI17E6) is a novel,
humanized monoclonal IgG2 antibody to the av subunit
[50]. It inhibits binding to av heterodimers, preventing
ECM attachment, cell motility and apoptosis, without
cross-reacting with other integrins (Fig. 1). In a phase 1,
placebo-controlled, dose-escalation study in healthy male
volunteers, the pharmacokinetics of abituzumab ap-
peared to be dose dependent, especially at lower doses
[60].
Abituzumab has been studied in several phase 1/2 on-
cology trials, demonstrating good safety and tolerability,
with potential anti-tumour activity in tumours with high
integrin anb6 expression [6163]. A phase 2 study of abi-
tuzumab is currently recruiting 175 patients with SSc-
ILD and DLCO530% predicted, FVC 4085% predicted,
FVC:DLCO ratio <1.8 and 55% lung fibrosis on HRCT
(ClinicalTrials.gov: NCT02745145; Eudra-CT: 2015-
005023-11) (Table 2). The study will assess abituzumab
plus immunosuppression and patients must have been
receiving a stable dose of MMF (1.53 g/day) or mycophe-
nolate sodium (10802160 mg/day) for 52 months before
screening. The primary endpoint is the annual rate of ab-
solute FVC change in volume (millilitres). Secondary end-
points include the following: 52-week changes in
breathlessness [as assessed by the Mahler Transition
Dyspnoea Index and St George’s Respiratory
Questionnaire (SGRQ)]; mRSS (in patients with diffuse cu-
taneous skin involvement at baseline); quantitative lung
fibrosis in the region of highest severity; 104-week
changes in DLCO, CO transfer coefficient, quantitative
lung fibrosis and extent of ILD on HRCT; clinically mean-
ingful progression of SSc-ILD at weeks 52 and 104; and
overall survival (assessed until death or end of trial).
Bortezomib
Bortezomib inhibits the ubiquitinproteasome proteolytic
pathway (Fig. 1), which degrades most short-lived intra-
cellular proteins involved in cellular processes such as the
cell cycle, differentiation and death, DNA repair, transcrip-
tion, signal transduction, morphogenesis, metabolism and
antigen presentation [64]. It is licensed for treatment of
multiple myeloma and mantle cell lymphoma and is
under investigation for treatment of solid tumours [64].
Bortezomib has immunomodulatory effects involving
immune cells, tumour-associated ligands and lympho-
cyte-activating receptors and cytokine signalling path-
ways [64]. In a mouse model, bortezomib promoted
normal repair and prevented the development of skin
and lung fibrosis after injury, a process related to inhibition
of TGF-b1-mediated target gene expression [65]. A phase
2, placebo-controlled study of bortezomib plus MMF vs
MMF is currently recruiting (ClinicalTrials.gov:
NCT02370693) (Table 2). Eligible patients have diffuse or
limited SSc and evidence of pulmonary fibrosis at high risk
of progression, with or without progressive skin disease.
The primary endpoint is safety and tolerability, with sec-
ondary endpoints including QoL (Promis-29, 36-item
Short Form and SGRQ dyspnoea score), mRSS, FVC
and serum biomarkers at 48 weeks.
Dabigatran
Vascular injury is central to SSc pathogenesis and, com-
bined with matrix deposition, leads to tissue hypoxia [66].
This in turn leads to epithelialmesenchymal transition via
TGF-b signalling or hypoxia-inducible factor 1, and a vi-
cious cycle of increasing fibrogenesis. Vascular injury is
also associated with activation of the coagulation cascade
and generation of thrombin, a potent stimulus for myofi-
broblast differentiation [66]. Dabigatran is a direct throm-
bin inhibitor that reversibly binds thrombin’s active site,
preventing conversion of fibrinogen to fibrin (Fig. 1) [67].
It is licensed for primary prevention of venous thrombo-
embolic events after joint replacement surgery, prevention
of stroke and systemic embolism in non-valvular atrial fib-
rillation and treatment of deep vein thrombosis and pul-
monary embolism.
In normal lung fibroblasts, dabigatran inhibits thrombin-
induced differentiation to the myofibroblast phenotype,
while in fibroblasts from patients with SSc, dabigatran de-
creases connective tissue growth factor, a-smooth
muscle actin and collagen type I [68]. In a mouse model
of lung injury, dabigatran attenuated the development of
injury-induced pulmonary fibrosis, with marked anti-
inflammatory and anti-fibrotic effects [69]. Dabigatran
(75 mg twice a day) is being investigated in an open-
label phase 1 study in 15 patients with SSc-ILD
(Table 2). The primary endpoint is a composite safety
measure of complete blood counts, comprehensive meta-
bolic profile and coagulation studies, while the main sec-
ondary endpoint is a composite efficacy measure
comprising skin score and dermal fibroblast biology.
Nintedanib
Nintedanib is a small-molecule tyrosine kinase inhibitor
acting on the PDGF, fibroblast growth factor and VEGF
receptors (Fig. 1) [70]. It interferes with fibrosis, including
fibroblast proliferation, migration and differentiation, and
secretion of ECM. Nintedanib is licensed for use in idio-
pathic pulmonary fibrosis (IPF) and is being investigated in
SSc-ILD in the phase 3 SENSCIS study (ClinicalTrials.gov:
NCT02597933) [71]. Patients are randomized to ninteda-
nib 150 mg twice a day or placebo and, to reflect real-
world management, patients receiving concomitant
prednisone 10 mg/day and/or a stable dose of MMF or
MTX are eligible. The primary endpoint is the annual rate
of FVC decline at week 52, with key secondary endpoints
including absolute changes from baseline in mRSS and
SGRQ at week 52.
Pirfenidone
Pirfenidone has anti-fibrotic and anti-inflammatory proper-
ties resulting from inhibition of IL-1b, IL-6, TNF-a and
PDGF [22]. It is licensed for treatment of IPF and was
investigated in the randomized, open-label, phase 2
LOTUSS study (ClinicalTrials.gov: NCT01933334) in 63
patients with SSc-ILD [72] to assess tolerability
https://academic.oup.com/rheumatology 9
Systemic sclerosis-associated interstitial lung disease
Downloaded from https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/key151/5035083
by Institute of Child Health/University College London user
on 20 June 2018
(Table 1). Patients received pirfenidone for 16 weeks using
either a 2- or 4-week titration schedule (starting dose
801 mg/day, maintenance dose 2403 mg/day). As pirfeni-
done is associated with an increased incidence of photo-
sensitivity, patients were instructed to avoid or minimize
sun exposure, use sunblock and wear protective clothing.
AEs were similar to those previously reported in IPF, most
commonly nausea, headache and fatigue. Tolerability was
generally better with the 4-week titration schedule, and
addition of MMF had no adverse impact on tolerability.
FVC% and DLCO were evaluated as exploratory end-
points and remained stable throughout the study [72].
This led to the launch of the SLS III study
(ClinicalTrials.gov: NCT03221257), which is assessing
whether the combination of immunosuppressive therapy
with MMF and anti-fibrotic therapy with pirfenidone has
greater efficacy than the immunosuppressant alone
(Table 1). The primary hypothesis is that the rapid onset
and anti-fibrotic effects of pirfenidone, as observed in IPF,
will complement the delayed anti-inflammatory and im-
munosuppressive effects of MMF to produce a signifi-
cantly more rapid and/or greater improvement in lung
function. The primary endpoint is the change in predicted
FVC% during the 18-month treatment period. Secondary
endpoints include the change in mRSS, extent of fibrosis
and total ILD on HRCT, predicted DLCO%, Transitional
Dyspnoea Index and other patient-reported outcomes
and time to achieve 53% improvement from baseline in
predicted FVC%. Identification of biomarkers is an ex-
ploratory endpoint. SLS III began recruiting patients in
November 2017.
Other agents
Several other agents are being investigated in patients
with SSc. While these studies are not specific to SSc-
ILD, they will include pulmonary endpoints. For example,
tocilizumab is an anti-IL-6 receptor humanized mAb that
blocks IL-6-mediated signalling (Fig. 1), implicated in SSc
pathogenesis in animal models [73]. It is licensed for treat-
ment of RA and is being investigated in the phase 3
focuSSced study in SSc (ClinicalTrials.gov: NCT02453
256; Table 2). SAR156597 is a mAb targeting IL-4 and
IL-13 (Fig. 1). The latter is associated with fibrogenic
remodelling, and SAR156597 is currently in phase 2 devel-
opment for the treatment of IPF [74, 75]. A phase 2 proof-
of-concept, placebo-controlled study of SAR156597 is also
under way in patients with dcSSc (ClinicalTrials.gov:
NCT02921971; Table 2).
In conclusion, SSc-ILD is a severely debilitating disease
with high mortality in extensive disease. There is no
approved disease-modifying treatment and few effective
treatment options are available. Key issues include vari-
able response rates, including non-response in some pa-
tients, slow response and drug toxicity. While CYC is an
option in the EULAR recommendations [26], it has limited
efficacy and issues with toxicity and is not licensed for
SSc-ILD. MMF is the most commonly used medication
in current best practice. Newer agents hold promise for
better treatment outcomes, including improved lung func-
tion, patient-related outcomes and QoL. In addition, an
article highlighting points to consider when designing clin-
ical trials in SSc has recently been published by the
EUSTAR research group [76].
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